Lancet Oncology

Papers
(The H4-Index of Lancet Oncology is 99. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Navigating the complexity: reflections on the development of perioperative cancer treatments681
Dual therapy in metastatic castration-resistant prostate cancer649
US FDA proposes stronger laboratory test oversight562
Enhancing equity and long-term impact assessments in radiotherapy environmental studies523
Palliative radiotherapy for hepatic cancer pain487
Driving two chimeric antigen receptors (CARs) in a row to reduce antigen escape in B-cell acute lymphocytic leukaemia485
Toxicity assessment bias in the PACE-C trial – Authors' reply427
New national cancer registry for France426
Neurotoxicity-related treatment discontinuations in PRODIGE 51-FFCD-GASTFOX399
Neurotoxicity-related treatment discontinuations in PRODIGE 51-FFCD-GASTFOX – Authors' reply386
Olanzapine for chemotherapy-induced nausea and vomiting control347
Study bolsters concerns about US FDA accelerated drug approvals323
Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in advanced ovarian cancer – Authors' reply315
Combination immunotherapy in chemotherapy in gastric cancer305
Use of artificial intelligence to enhance detection of nodal metastases296
The GLOW trial in chronic lymphocytic leukaemia295
Precision medicine for children with cancer289
Concern for cancer drugs in USA–EU tariff war284
Myung-Ju Ahn: battling sexism in medicine and supporting the next generation269
Combining enzalutamide and [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer268
IVLBCL mimicking VEXAS syndrome268
Radiotherapy has a role to play in patients with EGFR-mutated non-small-cell lung cancer in first-line treatment260
Correction to Lancet Oncol 2022; 23: 1124–26260
International Radiation Oncology societies Network (IRON): a unified voice in addressing global cancer challenges247
Determining the optimal use of approved drugs in oncology239
A new generation of comprehensive precision oncology trials235
Exploring the link between cancer policies and cancer survival: a comparison of International Cancer Benchmarking Partnership countries235
Italy to pass law on the right to be forgotten for cancer survivors232
Correction to Lancet Oncol 2021; 22: 1081–92229
Antibody–drug conjugates in acute myeloid leukaemia: more research needed229
Health insurance system in Japan faces risk of politicisation220
Nomogram-based risk classification for predicting response to metastasis-directed stereotactic body radiotherapy in PSMA PET-staged oligorecurrent prostate cancer (PORTAL): an international, retrospec217
Clinical benefit and the Trump administration's cancer medicine reforms213
The silent malignant mesothelioma epidemic: a call to action207
Real-world challenges and considerations in treating von Hippel-Lindau disease with HIF-2α inhibitors – Authors' reply205
SANO trial: innovations, risks, and unanswered questions202
Development of a conceptual framework for an electronic patient-reported outcome (ePRO) system measuring symptoms and impacts of CAR T-cell therapies in patients with haematological malignancies200
Non-invasive DNA methylation-based testing for the diagnosis of endometrial cancer194
Carcinogenicity of hepatitis D virus, human cytomegalovirus, and Merkel cell polyomavirus192
Innovation in gynaecological cancer: highlighting global disparities189
Psychosocial impact associated with a multicancer early detection test (PATHFINDER): a prospective, multicentre, cohort study189
Cabozantinib and temozolomide in patients with unresectable or metastatic leiomyosarcoma and other soft tissue sarcomas: a multicentre, single-arm, lead-in phase 2 trial188
Physical examinations and whole-body imaging versus physical examinations alone during follow-up after radical surgery of stage IIB–C and III cutaneous malignant melanoma (TRIM): an interim analysis o186
Discontinuation versus continuation of imatinib in patients with advanced gastrointestinal stromal tumours (BFR14): exploratory long-term follow-up of an open-label, multicentre, randomised, phase 3 t183
Sex disparity in childhood cancer in India: a multi-centre, individual patient data analysis178
Target volume delineation of the neck for radiotherapy in nasopharyngeal carcinoma: CSTRO, CACA, CSCO, HNCIG, ESTRO, and ASTRO guidelines and contouring atlas177
US Surgeon General calls for cancer warning labels on alcohol177
ALND after neoadjuvant chemotherapy: a call for caution174
Expanding the ADT-free therapeutic landscape in oligometastatic hormone-sensitive prostate cancer170
First Nations cancer inequalities in Canada169
Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor α-positive, platinum-resistant ovarian cancer: a randomised, 169
Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1–2, open-label, multicohort trial164
Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 157
Estimating global cancer survival and mortality from 1990 to 2050: a simulation-based analysis of 17 cancers156
Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial155
Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a mult152
Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial152
Multinational Association of Supportive Care in Cancer (MASCC) clinical practice guidelines for the prevention and management of acute radiation dermatitis: international Delphi consensus-based recomm148
Clinical and biological landscape of constitutional mismatch-repair deficiency syndrome: an International Replication Repair Deficiency Consortium cohort study143
Use of PROMISE criteria on PSMA-PET for prediction of overall survival in prostate cancer142
Mantle cell lymphoma: is it time for risk-adapted treatment?142
Lung cancer rates highest among British Bangladeshi men139
Cancer on the agenda during IAEA Director General's visit to Chile139
Balancing clinical benefit and social value: challenges in HTA assessments136
Daratumumab maintenance in patients with myeloma134
Clearing the radiotherapy backlog: innovation to pave the way133
Challenges and prospects for cancer treatment in prison settings133
Dose recommendations for anticancer drugs in patients with renal or hepatic impairment: an update133
Common Sense Oncology: including everyone132
Retroperitoneal fibrosis: carcinoid recurrence or histiocytosis?129
Dobbs v Jackson and fertility preservation among adolescents and young adults with cancer129
First-line talazoparib plus enzalutamide versus placebo plus enzalutamide in men with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: patient-repo123
ICGC-ARGO precision medicine: an update on targeted therapy based on longitudinal analysis of tumour heterogeneity and evolution in colorectal cancer123
Essential anticancer medicines for children: defining what matters most for Europe123
Importance of clinical research for the UK's 10-year cancer plan123
Decentralised, point-of-care CAR-T for multiple myeloma122
WHO reports health service disruptions due to suspensions of aid118
ESMO Congress 2025118
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk, early breast cancer – Authors' reply118
Canada's Yukon Territory publishes First Nations Cancer Strategy115
Assessment of endpoint definitions in recurrent and metastatic mucosal head and neck squamous cell carcinoma trials: Head and Neck Cancer International Group consensus recommendations115
Focus where it matters: turning insights into advocacy112
Daratumumab–lenalidomide and the immunosuppressive budget in myeloma – Authors' reply111
Dobbs v Jackson and access to fertility care among newly diagnosed adolescents and young adults with cancer in the USA110
2022 ASTRO annual meeting109
Correction to Lancet Oncol 2023; 24: e242107
Radiotherapy and conflict: from disruption to expansion and hope106
Syrian cancer patients regain treatment access in Türkiye106
Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-controlled, phase 1b/2 trial105
Findings suggest under-reporting of patient data in US SEER105
Antimicrobial resistance in patients with haematological malignancies: a scoping review105
Systemic therapy for brain metastases: a changing landscape105
The socioeconomic impact of cancer on patients and their relatives: Organisation of European Cancer Institutes task force consensus recommendations on conceptual framework, taxonomy, and research dire105
De-escalation of adjuvant radiotherapy in HPV-associated oropharyngeal cancer104
Oral contraceptives and risk of liver cancer104
Evaluation of progression-free status at 24 months as a surrogate endpoint for overall survival in patients with human papillomavirus-positive oropharyngeal cancer: a retrospective cohort study103
Carcinogenicity of hydrochlorothiazide, voriconazole, and tacrolimus101
Performance of the WID-qEC test versus sonography to detect uterine cancers in women with abnormal uterine bleeding (EPI-SURE): a prospective, consecutive observational cohort study in the UK99
From the European Medicines Agency to Project Orbis: new activities and challenges to facilitate UK oncology drug approval following Brexit99
0.22815990447998